Quoin Pharmaceuticals, Ltd. (QNRX)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-14 · Source: TEK2day Finance
Key Metrics
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (4.0M) | (4.5M) | (5.1M) | (5.5M) |
| Net Income | (3.9M) | (4.3M) | (5.0M) | (5.4M) |
| Diluted EPS | $-6.71 | $-1.74 | $-1.77 | $-1.90 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (9.3M) | (9.4M) | (9.5M) | (16.3M) |
| Net Income | (9.4M) | (8.7M) | (9.0M) | (15.8M) |
| Diluted EPS | $-1,638.23 | $-337.47 | $-66.85 | $-14.80 |